The Cor platform’s advanced ambulatory ECG capabilities transform healthcare, enabling faster, more accurate, and affordable diagnoses that enhance patients’ quality of life.
Proprietary algorithm to compute derived 12 lead
Hospital-grade diagnostics and monitoring anywhere, anytime (under trial)
The Peerbridge Cor is the voice of the heart, capturing 31 rhythms with superior recording fidelity, P-wave definition, and QRS morphology.
Early detection and treatment of heart failure can significantly improve patient outcomes and alleviate the strain on healthcare systems. Peerbridge Cor’s innovative remote monitoring solution enables timely and accurate diagnosis, even in asymptomatic individuals, presenting a more accessible and cost-effective approach than traditional methods.
By 2030, the predicted shortage of more than 120,000 cardiologists will significantly impact healthcare accessibility. Peerbridge Cor will be a leader in early, virtual diagnosis for patients in outpatient settings to reduce hospital stays and improve outcomes by measuring both normal and irregular beats with little disruption to a patients’ daily life.
With Peerbridge Cor, physicians can remotely monitor and deliver an accurate heart failure diagnosis within 30 minutes of applying Cor, compared to the current diagnosis timeline of 11-15 weeks with in-hospital screening tools.
Continuous monitoring of a patient’s heart activity while they go about their daily activities outside of a clinical setting.
On-demand diagnostics and screening tools with <10 minutes of wear.
Enabling simplified and accelerated research.
Wireless connectivity enablement with AT&T helps Peerbridge expand access to AI-driven cardiac care Peerbridge Health is ushering in the next generation of remote cardiac monitoring at the
Inexpensive wearable technology for diagnostics and monitoring has the power to transform cardiac care Peerbridge Health has announced the launch of its landmark COR-INSIGHT Trial, which
Peerbridge Health today announced the beginning of enrollment for its Ejection Fraction AI-enabled Clinical Trial (EF-ACT) pivotal trial to determine Left Ventricular Ejection Fraction